How Much Does CAR-T Cost in Switzerland?
The cost of CAR-T in Switzerland is USD 373000 - USD 500000
Additionally, factors like the duration of treatment, the need for follow-up care, and the use of advanced technologies or specialized treatments can further influence the overall cost.
Factors Influencing the Cost of CART:
- Type of Treatment: CART is a form of immunotherapy. Refers to the technique where a patient’s T-cells are genetically engineered to produce a receptor that home on proteins on cancer cells.
- Hospital and Location: This is equivocal because of the increased overhead cost that accompanies operations in large cities or urban areas compared to the countryside. It often costs more to stay in a private hospital or clinic.
- Surgeon’s Expertise: Very experienced or specialized surgeons, particularly those acknowledged as regional or international experts, may well be more expensive than the average.
- Pre-treatment tests: clinical investigations, mainly including imaging studies, blood tests, endoscopic examinations, and heart, lung, and kidney function tests. The performance of these tests enables the assessment of the general well-being of the patient and the possibility of surgery. These tests include X-ray, MRI, and CT.
- Post-Surgical Care: In addition to the price, the costs of aftercare, such as hospitalization, physiotherapy, anesthesia and pain medication, follow-up visits, and possible complications, will also be included.
- Length of Hospital Stay: Complex surgeries or complications may increase hospitalization costs.
CART is an acronym for a promising experimental type of cancer treatment called Chimeric Antigen Receptor T-cell therapy and mainly targets blood malignancies such as leukemia and lymphoma. This therapy is done by modifying the patient’s T-cells (one form of white blood cells) in the laboratory and making them have a receptor that homes in on cancerous cells. These engineered T-cells are then transduced back into the patient, they go on to hunt for cancer cells to kill.
CART therapy is rather effective, particularly in the cases of the treatment efficacy of which has not been rather impressive. It is individual treatment, which means that is independent of the cancer type in the patient. There are risks for cytokine release syndrome (CRS), as well as neurotoxicity that should be closely watched out for, but this option is hopeful for cancer patients who normally cannot be treated with conventional treatments.
Cost of CAR-T in Major Cities of Switzerland
| City | Minimum Cost (USD) | Minimum Cost (CHF) | Maximum Cost (USD) | Maximum Cost (CHF) |
|---|---|---|---|---|
| Lustmuhle | USD 335700 | 278631 | USD 450000 | 373500 |
CAR-T Cost : A Global Comparison
| Country | Minimum Cost | Minimum Local Currency | Maximum Cost | Maximum Local Currency |
|---|---|---|---|---|
| Czechia | get request | |||
| India | USD 80000 | INR 6851200 | USD 120000 | INR 10276800 |
| Lithuania | USD 300000 | LTL 1026210 | USD 500000 | LTL 1710350 |
| Malaysia | USD 75000 | MYR 318000 | USD 125000 | MYR 530000 |
| Saudi Arabia | USD 373000 | SAR 1398750 | USD 500000 | SAR 1875000 |
| Singapore | - | - | USD 475000 | SGD 612750 |
| Spain | USD 30000 | ESP 4411197 | USD 56000 | ESP 8234234 |
| Switzerland | USD 373000 | CHF 309590 | USD 500000 | CHF 415000 |
| Thailand | USD 150000 | THB 4906500 | USD 470000 | THB 15373700 |
| Tunisia | USD 100000 | TND 298000 | USD 200000 | TND 596000 |
| Turkey | USD 25000 | TRY 976500 | USD 55000 | TRY 2148300 |
| United Arab Emirates | USD 200000 | AED 734000 | USD 300000 | AED 1101000 |
| United Kingdom | USD 373000 | GBP 276020 | USD 475000 | GBP 351500 |
Need Help Planning Your Treatment Abroad?
Your 24/7 AI Health Assistant 
CAR T-cell therapy represents a groundbreaking approach to harnessing the power of the body's immune system to combat cancer. By modifying T cells, a subset of white blood cells, in a laboratory setting, these cells are empowered to recognize and eliminate cancer cells with precision. Often categorized as a form of cell-based gene therapy, CAR T-cell therapy involves altering the genetic makeup of T cells, equipping them with the ability to target specific cancer antigens.
This innovative treatment has demonstrated remarkable efficacy, particularly in cases where conventional therapies have proven ineffective. Its ability to reprogram the immune system to target and destroy cancer cells marks a significant advancement in cancer treatment strategies.
Classification:
CAR T cell therapy is classified as follows:
- Structure-based classification:
- First-generation CAR T-cells: These CAR T-cells typically consist of an antigen-binding domain (single-chain variable fragment, scFv) linked to a T-cell activation domain, such as the CD3ζ chain. They lack additional co-stimulatory domains.
- Second-generation CAR T-cells: These CAR T-cells include an additional co-stimulatory domain, such as CD28 or 4-1BB (CD137), along with the CD3ζ chain. The presence of co-stimulatory domains enhances T-cell activation and persistence.
- Third-generation CAR T-cells: These CAR T-cells incorporate two co-stimulatory domains along with the CD3ζ chain, aiming to further enhance T-cell function and anti-tumor activity.
Antigen-based classification: It includes
- CD19-targeted CAR T-cells: CD19 is a common target for CAR T-cell therapy and is used in the treatment of B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of lymphoma.
- Other antigen-targeted CAR T-cells: CAR T-cells can be engineered to target a variety of antigens expressed on cancer cells, including but not limited to BCMA (B-cell maturation antigen), CD22, CD30, and EGFRvIII.
- T-cell harvesting: T cells are removed from the patient's blood by processing.
- Genetic alteration: T cells are designed in the laboratory to express CAR proteins targeting cancer cells.
- Expansion: Modified T cells are expanded to therapeutic levels.
- Infusion: Patient receives an intravenous infusion of CAR T cells.
- Monitoring: Intensive monitoring, often in the hospital, for side effects and reactions.
- Cytokine Release Syndrome (CRS)
- Neurotoxicity
- Infections
- Low blood counts
- Relapse or non-response
Would you like some help? We are available.
Get Help
Paracelsus Clinic
Lustmuhle, Switzerland
Apart from in-detail treatment procedures available, Paracelsus Clinic located in Lustmuhle, Switzerland has a wide variety of facilities available for International Patients. Some of the facilities which are provided by them are Accommodation, Airport Transfer, Choice of Meals, Interpreter, SIM, TV inside room. Also listed below are some of the most prominent infrastructural details:
- Five large buildings that caters to 8000+ outpatients every year
- Medical staff of the Hospital includes 5 Doctors, 2 Dentists, 40+ nurses
- Paracelsus Pharmacy
- Paracelsus Dentistry
- Culinarium/Restaurant
Need Some Advice From Our Experts?
Request a Call Back Now!
Our team of healthcare experts would be happy to assist you
+99Process Involved for CAR-T in Switzerland
- Preoperative Stage: An assessment of the patient's medical history, including testing to determine eligibility for CAR-T therapy and identify the target antigen on cancer cells.
- Treatment Plan Discussion: An oncologist discusses the procedure of CAR-T therapy, including potential dangers, advantages, and side effects.
- Therapeutic Stage: T-cells are extracted from the patient, modified in the lab to express a chimeric antigen receptor (CAR), and reintroduced into the patient to target and destroy cancer cells.
- Postoperative Phase: Closely monitor for side effects. Follow-ups are scheduled regularly to check the response and treat any complications.
- Cancer patients, especially those suffering from blood cancers like leukemia, lymphoma, and multiple myeloma.
- Patients who have not responded to previous therapies, such as chemotherapy or radiation.
- Patients in good overall health with a functioning immune system.
- Individuals who have specific genetic markers that qualify them for CAR-T treatment.
- Targeted Action: CAR-T treatment specifically targets cancer cells, increasing efficacy while minimising damage to healthy cells.
- Potential for Remission: Can result in long-term remission, even in people with difficult-to-treat cancer.
- Minimally Invasive: The treatment consists mainly of an outpatient procedure for T-cell collection, with the therapy provided via infusion.
- Fill out the inquiry form: Fill out the form to provide us with the relevant information about your condition.
- Consult with Our Healthcare Expert: One of our qualified specialists will contact you for a consultation.
- Receive a Detailed Treatment Plan: After examining your situation, we will provide you with a detailed treatment plan that includes expert views and cost breakdowns for various choices.
- Choose your preferred option: Choose the treatment option that suits you the best.
